{"url_path":"/sec/mcrb/8-k/2026-06-01/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-251548-index.html","accession_number":"0001193125-26-251548","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-251548-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":136,"has_tables":true,"body_markdown":"Item 5.02.\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.\n\nOn May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026. Dr. Woerle’s departure is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nSERES THERAPEUTICS, INC.\n\nDate: June 1, 2026\n \n\n \nBy:\n \n\n/s/ Thomas J. DesRosier\n\n \n\n \nName:\n \nThomas J. DesRosier\n\n \n\n \nTitle:\n \nChief Legal Officer and Executive Vice President"}